Decurarization After Thoracic Anesthesia using sugammadex compared to neostigmine (DATA trial): a multicenter...

Area of Science:

• Anesthesiology
• Thoracic Surgery
• Pharmacology

Background:

• Thoracic surgery carries high risks, including postoperative pulmonary complications.
• Postoperative residual paralysis is a known risk factor for these complications.
• Limited data exist on neuromuscular blocking agent antagonists in lung surgery patients.

Purpose of the Study:

• To compare the efficacy of sugammadex versus neostigmine in reversing neuromuscular block after thoracic surgery.
• To evaluate the impact of these antagonists on recovery times and postoperative outcomes.

Main Methods:

• A randomized trial involving 70 patients across three Italian centers.
• Patients received either sugammadex or neostigmine based on neuromuscular block depth.
• Key outcomes included time to train-of-four ratio (TOFR) recovery, extubation, PACU discharge, complications, and hospital stay.

Main Results:

• Sugammadex demonstrated significantly faster recovery to a TOFR of 0.9 (median 88s vs. 278s) and 1.0 compared to neostigmine.
• A higher percentage of patients in the sugammadex group achieved TOFR 0.9 within 5 minutes (94.4% vs. 58.8%).
• Earlier extubation was observed with sugammadex, but PACU stay, complications, and hospital stay showed no significant differences.

Conclusions:

• Sugammadex provides faster neuromuscular block reversal and earlier extubation in thoracic surgery patients than neostigmine.
• These findings suggest sugammadex may be a preferred agent for optimizing recovery in this patient population.